News
最新消息 / 最新消息
教育訓練：「轉譯醫學」
課程日期： 113年10月31日(四) 課程時間： 15:00-16:00 課程地點： 線上閉門課程不對外開放 課程講師： 顧德諮詢有限公司/顧曼芹總經理
◇ COURSE SYLLABUS
◇ INSTRUCTOR﹍ DR. MANNCHING SHERRY KU
◇ POSITION﹍ GM OF KUDER CONSULTING INC.
◇ EDUCATION
◇ EXPERIENCE
- Introduction of Exposure Based Drug Development Program
- Prediction of Human Dose from Animal Studies
- Early Clinical Studies from SAD, MAD to POC. Case Study: Antidiabetic Drug
- Dose Selection Continuum from Laboratory to Bedside
- Q&A
◇ INSTRUCTOR﹍ DR. MANNCHING SHERRY KU
◇ POSITION﹍ GM OF KUDER CONSULTING INC.
◇ EDUCATION
- 9/78-9/83 Ph.D. in Pharmaceutics & Pharmaceutical Chemistry, The Ohio State University - GPA 3.88. Ph.D. Thesis on ADME including metabolite synthesis and C14 tissue distribution of Anticancer NCI contact Nucleosides under Professor Lou Malspeis.
- in Pharmacy, B.S.9/74-6/78 National Taiwan University
◇ EXPERIENCE
- Chairman of Board and Chief Executive Officer (CEO), Savior Lifetec Corp.
- Founding President and Board member of Ruenhuei Biopharmaceuticals, Inc.
- Founding President/CSO/Board member, TWi Biotech and TWi Pharma Inc.
- Pfizer Co, Pearl River, NY 10965 (previously Wyeth Research/American Cyanamid/Lederle)
- Vice Chairman, New Jersey Pharmaceutical Discussion Group
- Member of the Executive Yuan Biotechnology Industry Strategy Advisory Committee (BTC)
- In the 29-year tenure, she was promoted through the achievements: Developed more than 170 new clinical drugs, IND clinical research applications for 85 innovative new compounds and drugs, Successfully developed 9 marketed drugs, ect..